Pertuzumab biosimilar (Hisun Biopharma)

帕妥珠单抗生物类似药（杭州博之锐生物）

Report date: 2026/02/10 20:00:22

Base Information

Drug NamePertuzumab biosimilar (Hisun Biopharma)
Drug Alias Name贝泽汀
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2026/02/02
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHisun Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBettaHisun Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A